Filtered By:
Condition: Liver Disease

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 688 results found since Jan 2013.

NAFLD increases Risk of Carotid Atherosclerosis and Ischemic Stroke. An Updated Meta-Analysis with 135,602 Individuals
CONCLUSIONS: This meta-analysis shows that a stepwise increment of steatosis of NAFLD can significantly increase the odds of carotid atherosclerosis and stroke development in NAFLD. More than a third suffer from carotid atherosclerosis and routine assessment of carotid atherosclerosis is quintessential in NAFLD.PMID:35232007 | DOI:10.3350/cmh.2021.0406
Source: Clinical and molecular hepatology - March 2, 2022 Category: Gastroenterology Authors: Ansel Shao Pin Tang Kai En Chan Jingxuan Quek Jieling Xiao Phoebe Tay Margaret Teng Keng Siang Lee Snow Yunni Lin May Zin Myint Benjamin Tan Vijay K Sharma Darren Jun Hao Tan Wen Hui Lim Apichat Kaewdech Daniel Huang Nicholas Ws Chew Mohammad Shadab Siddi Source Type: research

High prevalence of non-alcoholic fatty liver disease in patients with a first episode of acute ischemic stroke. Impact on disability and death
ConclusionPresence of NAFLD did not impact on disability and death after the stroke. However, patients with a first episode of stroke showed a high prevalence of NAFLD, especially at intermediate ages, and therefore, screening for NAFLD should be advisable.
Source: Frontiers in Endocrinology - December 16, 2022 Category: Endocrinology Source Type: research

Efficacy and safety of carotid artery stenting for stroke prevention
Conclusion Careful patient selection and technique optimization are crucial to improve clinical outcome which make it a safe alternative for surgical revascularization in stroke prevention.
Source: The Egyptian Journal of Radiology and Nuclear Medicine - December 11, 2015 Category: Nuclear Medicine Source Type: research

Non ‐alcoholic Fatty Liver Disease is associated with stroke severity and progression of brainstem infarctions
ConclusionThese results suggest that NAFLD is a potential risk factor when evaluating the severity and progression of acute BSIs. This relationship is independent of classic risk factors and metabolic syndrome features.This article is protected by copyright. All rights reserved.
Source: European Journal of Neurology - December 27, 2017 Category: Neurology Authors: Haiyan Li, Biao Hu, Wei Lei, Li Zhou, Lei Zhang, Yinyao Lin, Bing Qin, Yongqiang Dai, Zhengqi Lu Tags: Original Article Source Type: research

A Museum of Stem Cells Points to Muse Cells as Robust Transplantable Cells for Stroke: Review.
Authors: Park YJ, Farooq J, Cho J, Cozene B, Gonzales-Portillo B, Sadanandan N, Saft M, Lee JY, Borlongan CV Abstract Stem cell-based therapy stands as a robust experimental treatment for ischemic stroke. Stem cells derived from fetal, embryonic, and adult tissues serve as potential sources for transplantable cells in the setting of ischemic stroke. However, the search continues for finding an optimal cell line for clinical use. Muse cells, a distinct subset of mesenchymal stem cells found sporadically in the connective tissue of nearly every organ, may be a suitable candidate due to its safety and accessibility. T...
Source: Advances in Experimental Medicine and Biology - November 11, 2020 Category: Research Tags: Adv Exp Med Biol Source Type: research

Nonalcoholic Fatty Liver Disease in Patients with Acute Ischemic Stroke is associated with more severe stroke and worse outcome.
There is a paucity of data regarding the association between non alcoholic fatty liver disease (NAFLD) and acute ischemic stroke. Stroke is largely preventable, so that knowledge of risk factors is essential to achieve reductions in the stroke rate and resulting disease burden.
Source: Journal of Clinical Lipidology - May 10, 2017 Category: Lipidology Authors: Sabry M. Abdeldyem, Tarek Goda, Samy A. Khodeir, Sabry Abou saif, Sherief Abd-Elsalam Source Type: research

Liver fibrosis-4 score predicts outcome of patients with ischemic stroke undergoing intravenous thrombolysis
Some evidence suggests a possible influence of liver disease on stroke prognosis. We investigated the association between fibrosis-4 (FIB-4) score, a marker of liver disease, and the 3-month outcome in patients with ischemic stroke undergoing intravenous thrombolysis. We also evaluated the rate of symptomatic intracranial hemorrhage after thrombolysis. In this prospective cohort study, we enrolled consecutive patients with ischemic stroke treated with thrombolysis who had a 3-month follow-up. The FIB-4 score was calculated and the validated cut-off values were used to indicate high/low risk of advanced liver fibrosis. The ...
Source: Frontiers in Neurology - February 24, 2023 Category: Neurology Source Type: research

Acute stroke-like presentation of acquired hepatocerebral degeneration
B. Smita, V. Abdul Gafoor, K. Saifudheen, James JoseAnnals of Indian Academy of Neurology 2014 17(2):204-206Neurological manifestations in liver diseases have been well-described. Parkinsonism developing in cirrhotic patients is a unique clinical, neuroradiological, and biological entity. The symptoms are often insidious in onset and occur after liver disease has made its presentation. Acute dysarthria as the presenting manifestation of cirrhosis is rare. Here we report three cases where liver disease made an unusual presentation as acute dysarthria. In all cases the abruptness of the onset prompted the treating physicians...
Source: Annals of Indian Academy of Neurology - May 17, 2014 Category: Neurology Authors: B. SmitaV. Abdul GafoorK. SaifudheenJames Jose Source Type: research

Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial
Pioglitazone, an antidiabetic drug, also exerts several cardiometabolic benefits including antioxidant, anti-inflammatory, antihypertensive, vasoprotective and hypolipidemic effects. These pioglitazone-related benefits have been observed in different patient populations such as those with prediabetes, non-alcoholic fatty liver disease and type 2 diabetes mellitus (T2DM). With regard to cardiovascular (CV) morbidity and mortality, there is conflicting evidence.Recently, the Insulin Resistance Intervention after Stroke (IRIS) trial reported a significant pioglitazone-induced decrease in CV morbidity in patients with insulin ...
Source: Journal of Diabetes and Its Complications - September 17, 2016 Category: Endocrinology Authors: Niki Katsiki, Dimitri P Mikhailidis Source Type: research

Association between nonalcoholic fatty liver disease with advanced fibrosis and stroke
There is an increasing appreciation of the cardiovascular implications of nonalcoholic fatty liver disease with advanced fibrosis (NAFLD-fibrosis). However, data regarding stroke risk are limited. We sought to investigate whether NAFLD-fibrosis is associated with stroke in addition to heart disease.
Source: Journal of the Neurological Sciences - October 12, 2019 Category: Neurology Authors: Neal S. Parikh, Lisa B. VanWagner, Mitchell S.V. Elkind, Jose Gutierrez Source Type: research

Nonalcoholic fatty liver disease with advanced fibrosis, stroke and cardiovascular disease
Parikh et al. conducted a cross-sectional study on the relationship of nonalcoholic fatty liver disease with advanced fibrosis (NAFLD-fibrosis) with stroke, heart disease, and major cardiovascular disease [1]. As indicators of NAFLD-fibrosis, the Fibrosis-4 Score (FIB-4) and NAFLD Fibrosis Score (NFS) were used for the analysis. Adjusted odds ratio (OR) (95% confidence interval [CI]) of the FIB-4 for stroke was 1.87 (1.00 –3.50). In addition, adjusted ORs of NAFLD-fibrosis for heart disease and major cardiovascular disease significantly increased.
Source: Journal of the Neurological Sciences - November 6, 2019 Category: Neurology Authors: Tomoyuki Kawada Tags: Letter to the Editor Source Type: research